18th week of 2010 patent applcation highlights part 46 |
Patent application number | Title | Published |
20100111917 | CELL-ADHESIVE POLYELECTROLYTE MATERIAL FOR USE AS MEMBRANE AND COATING - A multilayer polyelectrolyte support material is provided that includes a polyelectrolyte layer and a polyelectrolyte-polyethylene glycol layer adjacent to the polyelectrolyte layer. The support material also includes a ligand conjugated to the polyelectrolyte-polyethylene glycol layer, allowing for attachment of a protein or a cell to the support material with controlled orientation. | 2010-05-06 |
20100111918 | METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING - The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample. | 2010-05-06 |
20100111919 | DELAYED GELATION COMPOSITIONS AND METHODS OF USE - Biocompatible compositions are provided which may include at least one polysaccharide, at least one salt, and at least one reactive component. The at least one polysaccharide, at least one salt, and at least one reactive component may be in a single solution or multiple solutions and combined utilizing means within the purview of those skilled in the art. The compositions of the present disclosure experience delayed gelation, permitting their manipulation after application to tissue, which may be desirable for certain surgical and/or medical procedures, including cosmetic surgery. | 2010-05-06 |
20100111920 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VAGINAL DISEASES EMPLOYING PEROXIDE-PRODUCING ENZYMES AND PEROXIDASES - A therapeutic composition for vaginal administration based on the generation of a biocidal anion by an enzymatic reaction catalyzed by a peroxidase. The peroxide utilized by the peroxidase enzyme can be endogenous or can be generated by the action of an oxidase enzyme on a suitable substrate. Therapeutic compositions according to the present invention are useful for the treatment of vaginal diseases and conditions, including bacterial and fungal infections. | 2010-05-06 |
20100111921 | Use of IL-1 Antagonists to Treat Gout - Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited. | 2010-05-06 |
20100111922 | Animal model and use of 17beta-hydroxysteroid dehydrogenase type 7 in the diagnosis of anencephaly - The present invention features a non-human animal in which is deficient in the expression of endogenous 17β Hydroxysteroid Dehydrogenases Type 7 and use of the same in screening methods for agents that prevent or treat anencephaly. The present invention also provides a method for diagnosing and treating. | 2010-05-06 |
20100111923 | USE OF ALKALINE PHOSPHATASE IN THE TREATMENT OF REDUCED RENAL FUNCTION - The invention relates to the field of medicine and in particular to the use of alkaline phosphatase in the treatment of renal diseases, such as reduced renal function. The present invention also relates to the field of pharmacy and in particular to the pharmaceutical use of alkaline phosphatase. The present invention provides an alternative treatment to improve a situation in which the renal function is reduced by using alkaline phosphatase. | 2010-05-06 |
20100111924 | Chromosomal Modification Involving the Induction of Double-Stranded DNA Cleavage and Homologous Recombination at the Cleavage Site - Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases. | 2010-05-06 |
20100111925 | Compositions of Engineered Human Arginases and Methods for Treating Cancer - Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I. | 2010-05-06 |
20100111926 | Method of Using Salmon Thrombin to Alleviate Central Nervous System-Mediated Pain - A method of alleviating central nervous system-mediated pain includes applying salmon thrombin at a neural injury site. Applying salmon thrombin can include applying a gel that includes salmon thrombin. The gel can also include fibrinogen, for example, salmon fibrinogen, human fibrinogen, or bovine fibrinogen. The salmon thrombin can be obtained from salmon plasma, or using recombinant technology, or by fractionation. A pain relief substance includes a gel that includes salmon thrombin. | 2010-05-06 |
20100111927 | Compositions Comprising Actinidia and Methods of Use Thereof - Disclosed are novel preparations of | 2010-05-06 |
20100111928 | Methods and kits for diagnosis tumorgenicity - Methods and kits for diagnosing tumorigenicity by measuring the concentration of GP88 in blood, plasma, serum, saliva, urine and other biological fluids. The methods and kits detect GP88 in biological fluids at a concentration as low as about 0.1 to 10 nanograms per milliliter and are useful for determining whether a patient has a tumorigenic condition, whether the patient is likely to be responsive to anti-tumorigenic therapies, and whether the treated patient is responding to anti-tumorigenic therapy by measuring the concentration of GP88 in the patient's serum or other biological fluid. | 2010-05-06 |
20100111929 | METHOD OF TREATING PERIPHERAL NERVE DISORDERS - The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders. | 2010-05-06 |
20100111930 | Methods and Compositions for Detecting Receptor Ligand Mimetics - A method to determine the utility of small molecules as functional replacements (mimetics) for protein receptor ligands is described. The method uses cellular biological assays on a systematic array of compounds, comprising known protein receptor ligands and other biologically active molecules to determine if a proposed small molecule is a functional equivalent of a receptor ligand, having therapeutic utility as a pharmaceutically relevant and useful agent either alone or in combination with other molecules. | 2010-05-06 |
20100111931 | Agents, Which Inhibit Apoptosis in Cells that are Involved in Wound Healing - The invention relates to the use of substances as a fundamental constituent in wound healing agents. The invention is characterized in that said substances bond to either IAP and/or integrin α | 2010-05-06 |
20100111932 | ANTIBODIES AGAINST RAMP3 - The present invention provides an isolated antibody capable of binding a receptor activity modifying protein (RAMP) of CRLR receptor which antibody is of IgG, IgA or IgM isotype. | 2010-05-06 |
20100111933 | ACID SOLUBLE PROTEINS FROM MICELLAR CASEIN - The present invention relates to a milk fraction obtainable by acidification of micellar casein and separation from precipitated casein named acid soluble protein from micellar casein. It was found that the milk fraction and especially certain sub-fractions thereof are bioactive and promote GLP-1 release in vitro. Based on these results, acid soluble protein from micellar casein may be useful in the treatment and the prevention of diabetes type II, obesity and may further be added to formulas directed at other purposes addressing the gastro-intestinal tract. | 2010-05-06 |
20100111934 | Determining Immunoglobulins In Non-Blood Body Fluids Of Neonatal Ungulates - Provided is a method for determining immunoglobulins in a neonatal ungulate. The method entails obtaining a sample of oral secretions from the neonatal ungulate and measuring an amount of immunoglobulins in the sample of oral secretions. The method is faster and more convenient than previously available methods for determining immunglobulins in neonatal ungulates, such as neonatal horses and cattle. | 2010-05-06 |
20100111935 | Modulation of Toll-Like Receptor 2 Expression By Antisense Oligonucleotides - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR2. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR2 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR2 expression and for prevention or treatment of diseases wherein modulation of TLR2 expression would be beneficial are provided. | 2010-05-06 |
20100111936 | Modulation of Toll-Like Receptor 4 Expression by Antisense Oligonucleotides - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR4. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR4 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR4 expression and for prevention or treatment of diseases wherein modulation of TLR4 expression would be beneficial are provided. | 2010-05-06 |
20100111937 | Modulation of Toll-Like Receptor 5 Expression by Antisense Oligonucleotides - Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided. | 2010-05-06 |
20100111938 | Compositions and methods for biological remodeling with frozen particle compositions - Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue. | 2010-05-06 |
20100111939 | MONOCLONAL ANTIBODY AND USE THEREOF - The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided. | 2010-05-06 |
20100111940 | COMPOSITIONS CONTAINING ALPHA-1-ANTITRYPSIN AND METHODS FOR USE - Methods and compositions for treating patients (e.g., patients who are insulin resistant, patients who have diabetes, or are at risk for developing diabetes) are disclosed herein. The methods can include administration of an a1 antitrypsin (AAT) polypeptide or an agent, such as a nucleic acid molecule or organic compound, that promotes the expression or activity of a1-antitrypsin. | 2010-05-06 |
20100111941 | METHODS FOR TREATING CANCER - The invention relates to the treatment of abnormal or undesirable cell proliferation, particularly endothelial cell proliferation related to tumor growth. The compositions comprise anti-metastatic agents in combination with one or more anti-cancer agent. | 2010-05-06 |
20100111942 | COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR DISORDERS - The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention of a neovascular disorder. | 2010-05-06 |
20100111943 | COMPOSITIONS AND METHODS FOR INHIBITING CANCER METASTASIS - It has been discovered that antagonists of acetylated heat shock proteins can inhibit or reduce tumor cell invasion or metastasis. Compositions and methods for inhibiting tumor cell invasion or metastasis are provided. One embodiment provides a pharmaceutical composition including a heat shock protein antagonist in an amount effective to inhibit or reduce tumor cell invasion or metastasis. Another embodiment provides a pharmaceutical composition including a heat shock protein deacetylase in an amount effective to inhibit or reduce secretion of heat shock proteins. Representative target heat shock proteins include, but are not limited to hsp90α and hsp70. Methods of treating cancer or inhibiting tumor cell invasion and metastasis are also provided. | 2010-05-06 |
20100111944 | METHOD OF DIAGNOSING, CLASSIFYING AND TREATING ENDOMETRIAL CANCER AND PRECANCER - Diagnostic and therapeutic applications for endometrial cancer are described. The diagnostic and therapeutic applications are based on certain activation mutations in the FGFR2 gene and its expression products. The present invention is directed to nucleotide sequences, amino acid sequences, probes, and primers related to FGFR2 activation mutants and kits comprising these mutants to diagnosis and classify endometrial cancer in a subject. | 2010-05-06 |
20100111945 | NOVEL USES - The present invention relates generally to the use of human IL-18 combinations in the treatment of cancers. In particular, the present invention relates to combination of human IL-18 and an anti-CD20 antibody. | 2010-05-06 |
20100111946 | INHIBITING ACTIVATION WITH HUMAN ANTI-FACTOR C3 ANTIBODIES AND USE THEREOF - A method of inhibiting complement activation mediated by C3b inhibitors in a subject includes administering a C3B inhibitor to the subject to inhibit at least one of C3b binding to factors B and properdin, inhibit C3 cleavage, inhibit the activation of neutrophils, monocytes, platelets, and endothelium; or inhibit the formation of C3a, C5a, and MAC. | 2010-05-06 |
20100111947 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY COMPOSITION WHICH SPECIFICALLY BINDS TO GANGLIOSIDE GM2 - The present invention provides a pharmaceutical composition which is effective for treating multiple myeloma. The present invention relates to a pharmaceutical composition comprising a combination of an antibody composition which specifically binds to ganglioside GM2 or an antibody fragment thereof and at least one agent. | 2010-05-06 |
20100111948 | ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 2010-05-06 |
20100111949 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES - The invention features peptides containing domain 4 of the | 2010-05-06 |
20100111950 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 2010-05-06 |
20100111951 | ADAM-9 Modulators - The invention provides the identification and characterization of a disease and cancer-associated antigen, KID24. The invention also provides modulators of KID24, including a family of monoclonal antibodies that bind to antigen KID24, and methods of diagnosing and treating various human cancers and diseases with KID24. | 2010-05-06 |
20100111952 | TREATMENT OF AUTOIMMUNE DISORDERS - Methods of treating disease with soluble inhibitors of the lymphotoxin pathway having improved properties. Improved LTBR-Ig fusion proteins, and pharmaceutical compositions thereof, are also described. | 2010-05-06 |
20100111953 | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO B LYMPHOCYTE STIMULATOR - The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. | 2010-05-06 |
20100111954 | USE OF IL-23 AND IL-17 ANTAGONISTS TO TREAT AUTOIMMUNE OCULAR INFLAMMATORY DISEASE - Novel methods and drug products for treating autoimmune ocular inflammatory disease are disclosed, which involve administration of agents that antagonize one or both of IL-17 and IL-23 activity. | 2010-05-06 |
20100111955 | HEDGEHOG SIGNALING PATHWAY PROTEINS AND USES THEREOF - The present invention discloses a component in the hedgehog signaling pathway that can be useful in the treatment and diagnosis of hedgehog signaling pathway associated disorders. In this regard, the present invention discloses that RanBPM regulated the stability of hedgehog signaling molecule, smoothened (SMO) and that inactivation of RanBPM by siRNA prevented growth and metastasis of cancer cells. | 2010-05-06 |
20100111956 | ANTIGEN POLYPEPTIDE FOR THE DIAGNOSIS AND/OR TREATMENT OF OVARIAN CANCER - The invention provides an isolated antigen polypeptide that can be expressed in a subject with ovarian cancer. Also provided is the diagnosis of ovarian cancer by using the antigen polypeptide of the invention and the prevention and/or treatment of ovarian cancer by suppressing the gene of the antigen polypeptide of the invention. | 2010-05-06 |
20100111957 | METHODS OF DIAGNOSING AND TREATING CYTOMEGALOVIRUS DISEASES - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and wherein the antibody does not bind said peptide in an absence of said MHC molecule. Also provided are methods of using the antibodies. | 2010-05-06 |
20100111958 | Notch-Binding Agents and Antagonists and Methods of Use Thereof - The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth. | 2010-05-06 |
20100111959 | ENGINEERED ANTI-IL-13 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to engineered antibodies immunospecific for human interleukin-13 (IL-13) protein or fragment thereof, as well as methods of making and using thereof, including therapeutic indications. | 2010-05-06 |
20100111960 | ANTI-IL-20, ANTI-IL-22 AND ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION - The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners. | 2010-05-06 |
20100111961 | COMPOSITIONS AND METHODS FOR DIAGNOSING OR TREATING PSORIASIS - In one aspect, the present invention provides isolated nucleic acid molecules that encode a CAN-1 polypeptide, or an STG polypeptide. In another aspect, the present invention also provides isolated STG polypeptides, isolated CAN-1 polypeptides, and isolated SEEK-1 polypeptides. In another aspect, the present invention provides isolated antibodies that bind specifically to a CAN-1, SEEK-1 or STG polypeptide. In another aspect, the present invention provides methods of diagnosing or predicting the susceptibility to psoriasis of an individual. In another aspect, the present invention provides methods for ameliorating the symptoms and/or progression of psoriasis. | 2010-05-06 |
20100111962 | Determining and Reducing Immunoresistance to a Botulinum Toxin Therapy Using Botulinum Toxin B Peptides - The present invention provides BoNT/B peptides, BoNT/B peptide compositions, tolerogizing compositions, immune response inducing compositions, as well as methods of determining immunoresistance to botulinum toxin therapy in an individual, methods of treating immunoresistance to botulinum toxin therapy in an individual, methods of reducing anti-botulinum toxin antibodies in an individual and methods of inducing a BoNT/B immune response an individual. | 2010-05-06 |
20100111963 | METHOD FOR TREATING AGE-RELATED MACULAR DEGENERATION - A method is provided for administering to a mammal suffering from, or at risk for, age-related macular degeneration. | 2010-05-06 |
20100111964 | PLEIOTROPHIN GROWTH FACTOR RECEPTOR FOR THE TREATMENT OF PROLIFERATIVE, VASCULAR AND NEUROLOGICAL DISORDERS - This invention relates to the discovery that pleiotrophin binds to and activates a pleiotrophin-receptor which is responsible for the events associated with pleiotrophin activity including tumorigenesis, cell proliferation, and cell invasion. By interfering with that association, the cascade of events associated with pleiotrophin activity can be prevented or reversed. Further, by evaluating the effect of different compounds and conditions on the interaction, new drugs and treatments can be identified for use in preventing certain cancers and growth and developmental disorders. | 2010-05-06 |
20100111965 | COMBINATION THERAPY - The invention provides a method of treating neoplastic disease in a subject, said method comprising the simultaneous, sequential or separate, administration to said subject of an effective amount of (i) an inhibitor of a first EGF, e.g. HB-EGF and (ii) an inhibitor of a second EGF, e.g. AREG. Also described are novel synergistic combinations of EGF inhibitors with topoisomerase inhibitors which attenuate tumour cell growth. Further described are novel anti AREG antibodies. | 2010-05-06 |
20100111966 | ENGINEERED ANTI-IL-23P19 ANTIBODIES - Engineered antibodies to human IL-23p19 are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2010-05-06 |
20100111967 | BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES - The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2010-05-06 |
20100111968 | Methods for Mediating Fibrotic Response - Methods for mediating fibrotic response by modulating IL-25 signaling in fibrocytes are disclosed. | 2010-05-06 |
20100111969 | IL-4 RECEPTOR AND IL-13 AS PROGNOSTIC MARKERS FOR COLON AND PANCREAS TUMORS - The present invention relates to the use of IL-4 receptor and IL-13 expression as diagnostic and/or prognostic markers for tumors, such as colon and pancreas tumors. | 2010-05-06 |
20100111970 | Anti-NGF Antibodies and Methods Using Same - The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain. | 2010-05-06 |
20100111971 | ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 2010-05-06 |
20100111972 | Method for preventing or treating opiate tolerance and dependence - The present invention provides a method for preventing or treating opiate tolerance and dependence by administering to an individual in need of such treatment with a pharmaceutically effective amount of a blocking reagent for ephrinB-EphB signaling. The opiate tolerance and dependence can be caused by chronic morphine treatment and withdrawal. The blocking reagent can be an EphB receptor blocker such as EphB1-Fc and EphB2-Fc. | 2010-05-06 |
20100111973 | METHODS FOR TREATING MICA-RELATED DISORDERS - Disclosed herein are materials and methods for treating cancer. In particular, the compositions and methods for treating cancers associated with MICA overexpression are provided. | 2010-05-06 |
20100111974 | Treatment of Cachexia - The invention characterises and provides a receptor for Proteolysis Inducing Factor (PIF) and associated methods and materials employing the same. These have utility, for example, in the provision of treatments for cachexia. | 2010-05-06 |
20100111975 | Monoclonal Antibodies for Treatment of Cancer - The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer. | 2010-05-06 |
20100111976 | TARGETED BIOCIDES - The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing). The present invention also relates to methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in various diagnostic applications in number of diverse fields such as agriculture, medicine, and national defense. | 2010-05-06 |
20100111977 | Methods and compositions for treatment of myotonic dystrophy - In certain embodiments, the present invention provides compositions and methods for treating myotonic dystrophy. | 2010-05-06 |
20100111978 | CONJUGATES BETWEEN A VARIANT STAPHYLOCOCCAL ENTEROTOXIN E SUPERANTIGEN AND A TARGETING ANTIBODY THAT BINDS TO A CANCER-ASSOCIATED CELL SURFACE STRUCTURE - The present invention relates to compositions and methods of use, wherein the composition comprises a conjugate of a bacterial superantigen and an antibody moiety. More particularly, the bacterial superantigen has been modified to decrease seroreactivity with retained superantigen activity. | 2010-05-06 |
20100111979 | ANTIBODIES DIRECTED TO THE DELETION MUTANTS OF EPIDERMAL GROWTH FACTOR RECEPTOR AND USES THEREOF - The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided. | 2010-05-06 |
20100111980 | BINDING PARTNERS OF ANTIBODIES SPECIFIC FOR DENDRITIC CELL ANTIGENS - The present invention relates to the field of diagnostics, therapeutics and immunological reagents. More particularly, the present invention provides binding partners of antibodies specific for dendritic cell (DC) antigens. The present invention further provides diagnostic and/or therapeutic agent based on the binding partners or antibodies specific for the binding partners. | 2010-05-06 |
20100111981 | SYNTHETIC MONODISPERSE HEMOZOIN CRYSTALS PREPARATION AND USES THEREOF - A synthetic monodisperse hemozoin crystals preparation, compositions and methods of preparation thereof, are described. Also described are uses thereof, including use as an adjuvant, use in an immunogenic or vaccine composition, use for enhancing or inducing immunogenicity, and corresponding prevention or treatment of disease or infection. | 2010-05-06 |
20100111982 | RHEUMATOID ARTHRITIS T CELL VACCINE - Described herein is an activated synovial autoreactive T cell and compositions thereof. Methods or preparing T cell compositions that may be used for treating rheumatoid arthritis are also described. | 2010-05-06 |
20100111983 | Method for Using Lowstrength Electric Field Network (LSEN) and Immunosuppressive Strategies to Mediate Immune Responses - Application to an allograft or xenograft of a low strength electric field network (LSEN) together with an immuno-suppressive drug, gene and siRNA or other gene-based therapy is used to mediate the immune responses within an donor organ, tissue or cells, to prevent the acute and chronic rejection and to induce true tolerance, The gene(s) is locally transferred ex vivo in the time interval between harvest and implantation of allografts or xenografts before the implantation to introduce the long-term over expression of immunosuppressive and/or modulative molecules, or for down regulating alloreactive molecules in the donor organ, tissue or cells only and not in the recipient's whole body system. | 2010-05-06 |
20100111984 | NANOSPHERES ENCAPSULATING BIOACTIVE MATERIAL AND METHOD FOR FORMULATION OF NANOSPHERES - A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake. | 2010-05-06 |
20100111985 | VACCINE COMPOSITIONS AND METHODS OF USE - Described are a method and a composition for delivery of a protein to an antigen presenting cell. The composition is composed of a polypeptide component, a buffering component and a particle to be phagocytized. In one embodiment, the antigen presenting cell is aa macrophage or a dendritic cell and the particle to be phagocytized is from a natural source, such as from a microbial source. The composition itself, or cells pretreated with the composition, are useful for strategies in vaccine development. | 2010-05-06 |
20100111986 | WT1 HLA Class II-Binding Peptides and Compositions and Methods Comprising Same - This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same. | 2010-05-06 |
20100111987 | COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF NEOPLASTIC DISEASE IN A MAMMALIAN SUBJECT - Compositions and methods are provided for preventing or treating neoplastic disease in a mammalian subject. A composition is provided which comprises an enriched immune cell population reactive to a human endogenous retrovirus type E antigen on a tumor cell. A method of treating a neoplastic disease in a mammalian subject is provided which comprises administering to a mammalian subject a composition comprising an enriched immune cell population reactive to a human endogenous retrovirus type E antigen, in an amount effective to reduce or eliminate the neoplastic disease or to prevent its occurrence or recurrence. | 2010-05-06 |
20100111988 | SMALL PEPTIDE FOR ANTI-ANGIOGENESIS AND USE THEREOF - The present invention relates to a small peptide for anti-angiogenesis and use thereof, in particular, to a small peptide useful for treating angiogenesis diseases; a polynucleotide coding the peptide; a vector and a cell comprising the polynucleotide; a pharmaceutical composition comprising the small peptide, the fused peptide or the fused protein, the polynucleotide, the vector and/or the cell. The small peptide, the fused peptide or the fused protein, the polynucleotide, the vector, the cell and/or the pharmaceutical composition can be used for treatment of associated diseases such as tumor by anti-angiogenesis. | 2010-05-06 |
20100111989 | RSV F-PROTEIN AND ITS USE - The present invention relates to a nucleic acid molecule, which codes for the F-protein of the respiratory syncytial virus (RSV) or a fragment thereof, for the expression in a human cell environment of codon optimized variants of said nucleic acid molecule, vectors and compositions comprising said nucleic acid molecules and the use thereof as vaccines and polypeptides coded by the nucleic acid molecules and method for the production thereof. | 2010-05-06 |
20100111990 | Polypeptide Recognized by Anti HIV-1 GP41 Antibodies Isolated from Highly HIV-1 Exposed, Non Infected Women - The invention relates to a polypeptide recognized by anti HIV-1 gp41 antibodies isolated from Highly Exposed, non Infected Women, and epitopic fragments and conjugate thereof. Method of inducing antibodies neutralizing HIV-1 against HIV-1 is also contemplated. | 2010-05-06 |
20100111991 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P1E1B can be used in active or passive immunization. | 2010-05-06 |
20100111992 | CYTOMEGALOVIRUS PEPTIDES AND METHODS OF USE THEREOF - A method of modulating an immune response in a subject is disclosed. The invention is based on the discovery that an effective therapeutic strategy for ameliorating the symptoms of cytomegalovirus infection can be achieved by administering an effective amount of a CMV-derived peptide. | 2010-05-06 |
20100111993 | Recombinant vaccines and use thereof - The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule. | 2010-05-06 |
20100111994 | ANTI-BACTERIAL COMPOSITION AND METHOD OF USING SAME - Disclosed is an alkaline extract of pine cones with anti-bacterial activity. | 2010-05-06 |
20100111995 | Antigen conjugates and uses thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context. | 2010-05-06 |
20100111996 | Papaya Mosaic Virus-Based Vaccines for Influenza - An antigen-presenting system (APS) comprising one or more antigens in combination with a papaya mosaic virus (PapMV) or a virus like particle (VLP) derived from papaya mosaic virus is provided. Specifically an APS comprising one or more influenza virus antigens is provided. The APS can be used, for example, as a vaccine against influenza. The one or more antigens comprised by the APS can be conjugated to a coat protein of the PapMV or PaPMV VLP, or they may be non-conjugated (i.e. separate from the PapMV or PapMV VLP). Conjugation can be, for example, by genetic fusion with the coat protein, or binding via covalent, non-covalent or affinity means. | 2010-05-06 |
20100111997 | Multi component vaccine containing clostridial and non-clostridial organisms in a low dose - Disclosed herein is a multicomponent low dose vaccine comprising a safe and immunogenically effective combination of a protective antigen component or components of clostridial organism, a protective antigen component of a non-clostridial organism and an adjuvant. | 2010-05-06 |
20100111998 | HIV VACCINES BASED ON ENV OF MULTIPLE CLADES OF HIV - In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single Glade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens. | 2010-05-06 |
20100111999 | PRODUCTION OF POXVIRUSES WITH ADHERENT OR NON ADHERENT AVIAN CELL LINES - The present invention relates to a method for replicating poxviruses such as vaccinia virus comprising the steps of inoculating avian embryonic stem cells with viral particles and culturing said cells in a basal medium until cells lysis occurs and newly produced viral particles are released in said medium. | 2010-05-06 |
20100112000 | NON-TUMORIGENIC MDCK CELL LINE FOR PROPAGATING VIRUSES - The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention. | 2010-05-06 |
20100112001 | PURIFICATION OF VACCINIA VIRUS- AND RECOMBINANT VACCINIA VIRUS-BASED VACCINES - The present invention relates to methods for purification of Vaccinia viruses (VV) and/or Vaccinia virus (VV) particles, which can lead to highly pure and stable virus preparations of predominantly biologically active viruses. The invention encompasses purifying a virus preparation in a sterilized way with high efficiency and desirable yield in terms of purity, biological activity and stability, aspects advantageous for industrial production. | 2010-05-06 |
20100112002 | Modified Pathogens for Use as Vaccines - Described herein are microorganisms that are modified so that they have an increased ability to be recognized by the innate immune system of a eukaryote, relative to an unmodified microorganism. A microorganism may be a gram-negative bacterium that has been modified to produce high potency lipopolysaccharide, e.g., | 2010-05-06 |
20100112003 | BIFIDOBACTERIUM IN THE TREATMENT OF INFLAMMATORY DISEASE - A strain of | 2010-05-06 |
20100112004 | HYPOXIA INDUCIBLE FACTOR INDUCER AND METHODS FOR USING THE SAME - The present invention provides vaccine compositions and methods for using the same. Generally, the vaccine is used to prevent infection of a microorganism that produces an HIF inducing compound. Accordingly, vaccines of the invention comprise at least a portion of an HIF inducing compound that is produced by the microorganism. | 2010-05-06 |
20100112005 | Compositions of activated botulinum toxin type B - The present invention relates to pharmaceutical compositions of activated botulinum toxin type B. In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated—i.e., “nicked”. The invention also relates to a process of activating botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. The invention further relates to methods for the treatment of a variety of overactive or neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked. | 2010-05-06 |
20100112006 | Compositions of activated botulinum holotoxin type B (150 kD) - The present invention relates to pharmaceutical compositions of activated botulinum holotoxin type B (150 kD). In particular, the present invention relates to botulinum toxin type B pharmaceutical compositions wherein at least 90% of said botulinum toxin type B is activated (i.e., “nicked”), and wherein at least 99% said nicked botulinum toxin type B is a 150 kD holotoxin (i.e., “stripped”). The invention also relates to a process of activating and stripping botulinum toxin type B wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. The invention further relates to methods for the treatment of a variety of neuromuscular diseases, pain, inflammatory and cutaneous disorders comprising administering a pharmaceutical composition of activated botulinum holotoxin type B (150 kD) wherein at least 90% of said botulinum toxin type B is nicked, and wherein at least 99% of said nicked botulinum toxin type B is stripped. | 2010-05-06 |
20100112007 | TUBERCULOSIS VACCINE AND METHOD OF USING SAME - Provided is a pharmaceutical composition that includes one or more inactivated | 2010-05-06 |
20100112008 | TUBERCULOSIS NUCLEIC ACIDS, POLYPEPTIDES AND IMMUNOGENIC COMPOSITIONS - The present invention provides transcriptionally active Mtb polynucleotides, recombinant Mtb peptides and polypeptides, and immunogenic Mtb antigens. Immunogenic compositions are also provided that may be useful as recombinant, subunit and DNA vaccines. In addition the invention provides diagnostic kits for Mtb. | 2010-05-06 |
20100112009 | Acellular antibordetella vaccine - The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain of | 2010-05-06 |
20100112010 | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination - The present invention relates to a malaria vaccine for administration to a host, comprising an attenuated malarial parasite with a gene that has been rendered non-functional, wherein the gene, when present in naturally occurring form, encodes a protein necessary for continued in vivo survival and proliferation of the parasite and/or for infection of host red blood cells. The gene that has been rendered non-functional can be, e.g., a gene that encodes a nutrient transporter protein or a gene that encodes an enzyme involved in phospholipid biosynthesis. The invention also provides kits and methods that include such attenuated malarial parasites. | 2010-05-06 |
20100112011 | PHOTODYNAMIC THERAPY-GENERATED MESOTHELIOMA VACCINE - This invention relates to a vaccine for mesothelioma generated using photodynamic therapy and its use in methods and compositions for treating mesothelioma. | 2010-05-06 |
20100112012 | MODULATION OF IMMUNE RESPONSES - Compositions and methods for modulating an NF- | 2010-05-06 |
20100112013 | Adjuvant comprising oligonucleotide and non-toxic lipopolysaccharide - Disclosed is an adjuvant composition of the present invention including the oligodeoxynucleotides and the LPS-derived non-toxic polysaccharides as the major components. | 2010-05-06 |
20100112014 | NOVEL HYDROGEL COMPOSITIONS AND METHODS OF USING - Disclosed are novel agarose, methylcellulose, and dextran hydrogels. Further disclosed are methods of making and using the hydrogels. | 2010-05-06 |
20100112015 | Orally administered agent and an orally administered agent/supporting substrate complex - With an object of providing an orally administered agent (in particular a film-shaped orally administered agent) with which the ease and safety of taking the agent are improved, to attain this object, in an orally administered agent | 2010-05-06 |
20100112016 | OPHTHALMIC OIL-IN-WATER EMULSIONS CONTAINING PROSTAGLANDINS - The present invention refers to an oil-in-water emulsion for ophthalmic application comprising at least one prostaglandin as active agent and a surfactant component comprising a combination of at least two non-ionic surfactants. The emulsion is suitable for medical applications, particularly for the treatment of glaucoma, and has an increased chemical stability of the prostaglandin active agent so to allow long-term storage also at room temperature. | 2010-05-06 |